PresentationWelcome to the Immuneering conference call to discuss the positive 12-month overall survival update from the company's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients. [Operator Instructions] As a reminder, this call is being recorded today, Wednesday, January 7, 2026. I would now like to turn the conference over to Courtney Dugan, Vice President, Head of Investor Relations. Please go ahead.Courtney Dugan Thank you, operator. Joining us on the call today from Imm ...

Core Points - The conference call is focused on the positive 9-month update from Immuneering's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients [1] - Key executives from Immuneering, including the CEO and Chief Scientific Officer, are present on the call to discuss the trial results and future plans [2] Company Updates - Immuneering is currently conducting a Phase IIa trial for atebemetinib, which is aimed at treating first-line pancreatic cancer patients [1][3] - The management team is expected to provide forward-looking statements regarding the trial and the timing of additional data [3][4]